Markets:

Overview

News

Currencies

International

Treasuries

Johnson & Johnson (NY:JNJ)

238.26 +2.99 (+1.27%)

Streaming Delayed Price Updated: 10:09 AM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

The Fear Gauge Ascendant: VIX Hits 26 as Geopolitical Storms and 'Higher-for-Longer' Reality Grip Markets

March 24, 2026

The CBOE Volatility Index (VIX), Wall Street’s premier measure of expected stock market volatility, climbed to a reading of 26.15 this week, marking its highest sustained level in nearly two years. As...

Via MarketMinute

If You Only Own Tech Stocks, Jim Cramer Has a Blunt Warning for You in 2026 ↗

March 23, 2026

CNBC commentator Jim Cramer sees value in the artificial intelligence (AI) realm beyond the technology sector.

Via The Motley Fool

Topics Artificial Intelligence Economy Stocks

FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market

March 23, 2026

In a landmark decision for the dermatology sector, the U.S. Food and Drug Administration (FDA) has officially approved ICOTYDE™ (icotrokinra), a first-of-its-kind oral peptide for the treatment of...

Via MarketMinute

Johnson & Johnson (JNJ) Forecast: Extended Rally Signals Patience for Buyers ↗

March 17, 2026

Via Talk Markets

Johnson & Johnson (NYSE:JNJ): A Dividend King Built for Sustainable Passive Income ↗

March 07, 2026

Via Chartmill

1 Dividend ETF That Could Turn $500 Monthly Into a $725,000 Portfolio That Pays $21,750 Annually ↗

March 20, 2026

Patience can pay off with this high-yield dividend ETF.

Via The Motley Fool

Topics ETFs

Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie ↗

March 19, 2026

FDA approves Icotyde, a once-daily psoriasis pill from Johnson & Johnson, sparking new competition in treatment options.

Via Benzinga

2 Reasons to Buy Johnson & Johnson Stock Like There's No Tomorrow ↗

March 19, 2026

This stock is one to own during any market environment.

Via The Motley Fool

Topics Artificial Intelligence

AbbVie Shares Retreat to Multi-Month Lows Amid Competitive Headwinds and Technical Breakdown

March 18, 2026

The pharmaceutical giant AbbVie (NYSE: ABBV) experienced a sharp decline on Wednesday, March 18, 2026, as its stock price tumbled to its lowest level since mid-2025. Shares of the Illinois-based...

Via MarketMinute

Topics ETFs Economy Intellectual Property

The High-Stakes Gambit: How Healthcare Giants are 'Front-Loading' Megadeals to Outrun Regulatory Storms

March 18, 2026

In the face of the most aggressive antitrust environment in decades and the sweeping legislative changes of the 2025 "One Big Beautiful Bill Act" (OBBBA), the healthcare sector has not retreated from...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

2 Stocks That Could Create Lasting Generational Wealth ↗

March 17, 2026

These investments could help you sleep peacefully at night.

Via The Motley Fool

Topics World Trade

The $40 Billion Pivot: Kimberly-Clark and Kenvue Merger Redefines the Consumer Staples Landscape

March 16, 2026

In a move that signals a seismic shift in the global consumer goods sector, Kimberly-Clark (NYSE:KMB) is charging forward with its landmark $48.7 billion enterprise value acquisition of consumer health...

Via MarketMinute

Topics Artificial Intelligence Lawsuit

Your Tax Refund Will Probably Be Bigger This Year. Here's What to Do With It. ↗

March 16, 2026

There are still reliable stocks to consider for investing your tax refund this year.

Via The Motley Fool

Topics Economy Retirement

Stryker Corporation (SYK): Navigating Innovation and Resilience in the Wake of a Digital Crisis

March 16, 2026

As of March 16, 2026, the medical technology landscape is grappling with a stark reminder of the vulnerabilities inherent in the digital shift of healthcare. Stryker Corporation (NYSE: SYK), a global...

Via Finterra

Topics Earnings Economy Hacking

Johnson & Johnson’s Trial In Early-Stage Bladder Cancer Yield Positive Safety Results ↗

March 13, 2026

The study also demonstrated complete and durable responses in patients with recurrent intermediate-risk disease, along with encouraging recurrence-free outcomes in high-risk disease, the company said.

Via Stocktwits

Flight to Quality: JPMorgan and Eli Lilly Emerge as Defensive Anchors Amid Geopolitical Storm

March 13, 2026

In a day marked by heightened global tensions and a sharp spike in energy prices, the U.S. equity markets witnessed a decisive "Great Rotation" as investors abandoned high-growth technology names in...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

The Best Dividend Stocks to Buy and Hold Forever ↗

March 12, 2026

They are relatively safe wealth compounders.

Via The Motley Fool

Topics Intellectual Property

1 No-Brainer S&P 500 Vanguard ETF to Buy Right Now for Less Than $1,000 ↗

March 12, 2026

During times of uncertainty, this ETF makes a great buy.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE)

March 12, 2026

Date: March 12, 2026Sector: Biotechnology / NeurologyMarket Cap: ~$4.8 Billion Introduction On March 9, 2026, the neurology sector of the biotechnology market witnessed a seismic shift. Xenon...

Via Finterra

Topics ETFs Intellectual Property

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

March 12, 2026

From Johnson & Johnson

Via Business Wire

End of an Era: West Pharmaceutical Shares Slide as Longtime CEO Eric Green Announces Retirement

March 11, 2026

Shares of West Pharmaceutical Services (NYSE: WST) tumbled 5.7% on Tuesday following the announcement that Eric Green, the company’s President, Chief Executive Officer, and Chair of the Board, intends...

Via MarketMinute

Topics Economy Retirement

Cracks in the Bull Case: S&P 500 Breaches Key Support as Institutional Distribution Takes Hold

March 11, 2026

The multi-year bull market that defined the mid-2020s is facing its sternest test yet. On March 11, 2026, the S&P 500 index decisively breached the critical 6,764 support level, a technical floor that...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Safe Haven in a Storm: Healthcare Leads Markets as Geopolitical Tensions Spark Defensive Rotation

March 10, 2026

On a day marked by deepening global uncertainty and a sharp spike in energy costs, the healthcare sector emerged as the primary beneficiary of a massive "risk-off" migration by institutional investors....

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Quiet Outperformance From an Overlooked Dividend ETF ↗

March 09, 2026

Via MarketBeat

2 No-Brainer Dividend Stocks to Buy in 2026 ↗

March 08, 2026

Their futures look bright, and their dividends are safe.

Via The Motley Fool

Topics Intellectual Property

These 7 Elite Dividend Stocks Pay $114 Billion Annually, Combined, to Their Shareholders ↗

March 08, 2026

Seven of Wall Street's most influential businesses are doling out between $11.9 billion and $27.1 billion to their investors each year.

Via The Motley Fool

Topics Artificial Intelligence

FDA Clears Johnson & Johnson's Multiple Myeloma Combo Drug After Strong Survival Results ↗

March 06, 2026

FDA approves Johnson & Johnson's Tecvayli with Darzalex Faspro for multiple myeloma after strong Phase 3 survival results.

Via Benzinga

Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion

March 05, 2026

EQNX::TICKER_START (NNASDAQ:HELP),(CBOE:HELP),(NASDAQ:ACHC),(NYSE:JNJ),(NASDAQ:BWAY),(NASDAQ:AIFF) EQNX::TICKER_END

Via FinancialNewsMedia

2 Top Defensive ETFs That Prioritize Stability Over Excitement ↗

March 04, 2026

If you're worried about downside risk right now, here are two smart choices.

Via The Motley Fool

Topics Artificial Intelligence ETFs World Trade

ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth

March 04, 2026

In a classic case of "selling the news," shares of ImmunityBio, Inc. (NASDAQ: IBRX) took a sharp dive on Wednesday, March 4, 2026, plummeting over 13% to close at $9.02. The sell-off came as a surprise...

Via MarketMinute

Topics Earnings Economy

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.